Press Releases
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
SINGAPORE, JANUARY 12, 2023: Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences® (Caris)’ molecular profiling services in South East Asia. Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. The company’s … Read more
Read MoreHelsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more
Read MoreJuniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
Juniper Biologics Pte Ltd announced today the signing of an exclusive license agreement to develop and commercialise infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.
Read MoreJuniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis
$600 million USD acquisition will see Juniper Biologics offer the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa.
Read MoreJuniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)
Helsinn Healthcare SA announced the signing of exclusive distribution, license and supply agreements for Aloxi®, Onicit®, Paloxi®, Akynzeo® (IV and oral formulations) and anamorelin (INN).
Read MoreJuniper Biologics Announces the Appointment of Raman Singh as Chief Executive
Juniper Biologics has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.
Read More